Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131431) titled 'A retrospective study on efficacy and safety of conversion ablation therapy for hepatocellular carcinoma' on Sept. 2.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The Fifth Medical Center of Chinese PLA General Hospital
Condition:
Hepatocellular carcinoma
Intervention:
Lenvatinib plus PD-1/PD-L1 inhibitor group:N/A
Recruitment Status: Not Recruiting
Phase: Retrospective study
Date of First Enrollment: 2026-09-02
Target Sample Size: Lenvatinib plus PD-1/PD-L1 inhibitor group:77;Bevacizumab plus PD-1/PD-L1 inhibitor group.:77;
Countries of Recruitment:
China
To know ...